Neurocrine Biosciences Inc (NAS:NBIX)
$ 141.91 -0.09 (-0.06%) Market Cap: 14.28 Bil Enterprise Value: 13.58 Bil PE Ratio: 39.09 PB Ratio: 5.98 GF Score: 89/100

Neurocrine Biosciences Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 11, 2019 / 05:00PM GMT
Release Date Price: $82.36 (+0.37%)
Kyuwon Choi
Goldman Sachs Group Inc., Research Division - Equity Analyst

Good morning, everyone. I'm Paul Choi, the U.S. mid-cap biotechnology analyst. And with me is Corinne Jenkins from the team. We're very pleased to host Neurocrine Biosciences with the next session here. To my left is Kevin Gorman, CEO; and to his left, Matt Abernethy, CFO. I think this is relatively a well-known company, but let's, Kevin, kick off with some brief introductory remarks. And then we'll go into Q&A after that.

Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director

Sure. Thank you, Paul, and thank you, Goldman Sachs, for the opportunity to get together and talk with you today.

Before I start, we'll be making forward-looking statements here. So I would direct you to our recent SEC filings for all the applicable warnings and risks associated with the company.

Neurocrine is a company that's been around for quite a while, about 25 years now. We in the past 2 years have had our first 2 drugs approved, INGREZZA for tardive dyskinesia, a movement

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot